Spectral-CT fat quantification in patients with end-stage liver disease

Recruiting

• Conditions: Hepatic steatosis, end-stage liver disease, hepatocellular carcinoma, ascites; M62.5; Muscle wasting and atrophy, not elsewhere classified

• Registration Number: DRKS00027124
• Lead Sponsor: Department of Diagnostic and Interventional Radiology and Nuclear Medicine and Department of Liver Transplantation, University Medical Center Hamburg-Eppendorf

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-02
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

Evaluation for liver transplant listing.
- Clinical indication for a CT scan

Exclusion Criteria

- MRI contraindications
- Spondylodesis material at the level of the 3rd lumbar vertebra

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of patients in whom the dual-layer spectral CT fat quantification is applicable versus the number of patients in whom both, dual-layer spectral CT and MRI provide results for the group of patients with and without ascites.<br>Agreement and variance of dual-layer spectral CT and MRI fat quantification results for the liver and the skeletal muscle.

Secondary Outcome Measures

Name	Time	Method
1. Relationship of the dual-layer spectral CT muscle fat values ??to single-energy CT sarcopenia parameters and to clinical muscle parameters.<br><br>2. Relationship of the radiological and clinical parameters to the clinical course and quality of life.